Skip to main content
AVTXAvalo Therapeutics, Inc.Hold5.6·$6.76
AVTX · Why this verdict

Why Avalo Therapeutics (AVTX) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Avalo is a pre-revenue, cash-burning biotech with single-program and single-supplier concentration, a confirmed downtrend and insider selling; its only support is a large but lightly covered analyst upside.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Value depends on one pipeline asset, abdakibart (AVTX-009), manufactured by a single CDMO, with 3 HIGH concentration risks flagged.

→Stable
Risk breakdown
Expectation
Pipeline progress or supplier diversification reduces the HIGH concentration risks flagged.

CounterA setback in abdakibart or at the single manufacturer would hit the whole company with no other program to cushion it.

Analysts see 415% upside, but coverage is light and the raw $34.80 target was rejected as implausible against a $6.76 price.

→Stable
Sentiment breakdown
Expectation
Price holds above support near $6.33 as pipeline milestones are reached and coverage broadens.

CounterThe 5.1x gap between the raw target and price was rejected as implausible, so the upside signal may not be reliable.

The company is cash-burning with free cash flow at -32849% of revenue and revenue at zero in each of the last three quarters.

→Stable
Quality breakdown
Expectation
Revenue becomes meaningful and cash burn narrows over the next 12 months.

CounterWithout revenue, funding needs may force dilutive raises that hurt shareholders even if the science works.

Momentum is 3.4 (below the engine's 4.5 threshold) with a death cross, falling on-balance volume and a 200-day average sloping down 7.1% over 30 days.

↑Improving
Momentum breakdown
Expectation
Momentum recovers above 4.5 as the stock stabilizes after a 72% drawdown.

CounterThe MACD is already improving and RSI is 44, so the downtrend may be close to exhaustion.

Insiders are net sellers, with 3 sales worth $395,474 in 90 days and no buys, a bearish signal.

→Stable
Insider
Expectation
Insider selling stops and buying appears over the next 12 months.

CounterThe sales are only 0.101% of market cap, which is minor and may reflect routine compensation-related selling.

Per-dimension breakdown

Value

10.0/10data confidence 20%
ComponentSub-score
EV/EBITDA10.0
  • ▸Attractively valued

Quality

1.8/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Net margin0.0
Current ratio5.0
FCF quality0.0
Moat4.8
Piotroski F4.4
  • ▸Cash-burning: FCF -32849% of revenue
  • ▸No competitive moat
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

3.4/10data confidence 100%
ComponentSub-score
RSI4.5
MACD10.0
OBV1.0
MA position1.0
Volume0.7
  • ▸Volume distribution (falling OBV)
  • ▸Below 200-MA, MA slope -7.1%/30d — confirmed downtrend

Sentiment

7.7/10data confidence 100%
ComponentSub-score
Analyst rating8.2
Price target10.0
erm sentiment4.1
  • ▸Light analyst coverage (10.0) — signal dampened
  • ▸Analyst upside: 415%

Insider

5.5/10data confidence 100%
ComponentSub-score
materiality3.0
insider conviction2.0
holder change9.9
notable moves7.0
  • ▸Notable insider selling — $395,474 (0.101% of mkt cap)
  • ▸Institutions accumulating

Peer rank

6.2/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank4.8
growth rank5.0
  • ▸Conservative debt levels

Technical

5.5/10data confidence 100%
ComponentSub-score
bollinger7.3
support resistance8.9
52w position0.0
gap6.0

Risk (lower is worse)

5.3/10data confidence 100%
ComponentSub-score
short interest1.8
days to cover7.3
volatility0.0
put call9.6
implied vol0.0
beta8.5
debt equity10.0
  • ▸High short interest justified: 17%
  • ▸High IV: 85%
  • ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.0/10data confidence 100%
ComponentSub-score
erm3.5
earnings history6.7
earnings timing5.0
surprise avg10.0
news activity5.0
  • ▸Strong earnings: 3B/1M

How the verdict was assembled

Engine trigger

Market cap $391M below $400M minimum. Not in investable universe.

Engine technical detail
verdict_path: L1:HARD_BLOCK:MARKET_CAP
Passed (5)
  • INSIDER:OK
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:101d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • MOMENTUM:3.4<4.5
  • DEATH_CROSS:HARD_BLOCK
Warning (2)
  • ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+24.0%
Downside
15.0%
Sizing output
AVOID

SetupRecovery — Death cross but MACD improving, RSI 44

EdgeInst Constrain — Small cap ($0.4B) below institutional reach

SuitabilitySpeculative — Drawdown -72% (>40% off 52w high), Binary industry: Biotechnology

Investment implication

The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 3.4<4.5 outcome against Value at 10.0 and asymmetric R:R of 0.00.

The strongest dimensions are Value at 10.0, Sentiment at 7.7, and Peer rank at 6.2; the weakest are Quality at 1.8, Momentum at 3.4, and Growth at 5.0. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Analyst Upside Pipeline Value

    Trip ifStock price falls below $5.00 from the current $6.76.

  • P2Single Program Supplier Concentration

    Trip ifHIGH concentration risk count falls below 2 from the current 3.

  • P3Pre Revenue Cash Burn

    Trip ifQuarterly revenue exceeds $5M from the current $0.

  • P4Confirmed Downtrend Momentum

    Trip ifMomentum score rises above 5.0 from the current 3.4.

  • P5Insider Net Selling

    Trip ifTotal insider buy value over 90 days exceeds $100,000.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › AVTX › Why this verdict